Treatment of symptomatic patients with essential thrombocythemia: Effectiveness of anagrelide

We prospectively evaluated the effect of anagrelide (ANA) on platelets, PF4, F1+2, PAP, PAI‐1, and TFPI and erythromelalgia in patients with essential thrombocythemia (ET) receiving anti‐aggregants both pre‐ and post‐ANA. At first, we observed a successful reduction of platelets, which was associated with normalization of platelet coagulant and endothelial function and disappearance of erythromelalgia. Secondly, we found a correlation between PF4 and TFPI and between TFPI and thrombosis, suggesting that erythromelalgia may be caused by platelet‐mediated endothelial activation. These data may indicate that ANA may be efficacy in the treatment of symptomatic patients with ET. Am. J. Hematol. 80:81–83, 2005. © 2005 Wiley‐Liss, Inc.

[1]  T. Barbui,et al.  Chronic myeloproliferative disorders. , 2003, Hematology. American Society of Hematology. Education Program.

[2]  J. Birktoft,et al.  Structure and Biology of Tissue Factor Pathway Inhibitor , 2001, Thrombosis and Haemostasis.

[3]  R. Marta,et al.  State-of-the-Art Review : Effectiveness of Anagrelide in the Treatment of Symptomatic Patients with Essential Thrombocythemia , 2000, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[4]  R. Marta,et al.  [Thromboxane B2 and platelet derived growth factor in essential thrombocythemia treated with anagrelide]. , 2000, Medicina.

[5]  P. V. van Genderen,et al.  Thromboxane‐dependent platelet activation in vivo precedes arterial thrombosis in thrombocythaemia: a rationale for the use of low‐dose aspirin as an antithrombotic agent , 1999, British journal of haematology.

[6]  S. Murphy.  Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia. , 1999, Seminars in hematology.

[7]  P. V. van Genderen,et al.  Erythromelalgia in Essential Thrombocythemia Is Characterized by Platelet Activation and Endothelial Cell Damage but not by Thrombin Generation , 1996, Thrombosis and Haemostasis.

[8]  M. Boffa,et al.  Platelet Hyperactivation in Patients with Essential Thrombocythemia Is not Associated with Vascular Endothelial Cell Damage as Judged by the Level of Plasma Thrombomodulin, Protein S, PAI-1, t-PA and vWF , 1993, Thrombosis and Haemostasis.

[9]  A. Schafer.  Bleeding and thrombosis in the myeloproliferative disorders. , 1984, Blood.